Every 8-K that Mereo BioPharma Group plc American (MREO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MREO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MREO filings page.
Mereo BioPharma Group plc (MREO) reports it has received a second notice from Nasdaq that its American Depositary Shares remain below the $1.00 per share minimum bid price required for continued listing on the Nasdaq Capital Market. The company has been granted an additional 180-day compliance period, until February 16, 2027, to meet this Bid Price Requirement by achieving a closing bid of at least $1.00 for 10 consecutive business days. If compliance is not regained by that date, Nasdaq staff will move to delist the securities, though Mereo would be able to appeal to a Nasdaq Hearings Panel. The company states that the notices have no immediate effect on trading and that it will continue monitoring its share price and may consider options to regain compliance.
Mereo BioPharma Group plc reported second-quarter 2026 results, highlighting a smaller net loss and an extended cash runway alongside key partnering progress. Net loss for the quarter was $7.0 million, improving from $14.6 million a year earlier, driven mainly by sharply lower research and development spending.
As of June 30, 2026, cash and cash equivalents were $30.1 million, which the company expects will fund operations into late 2027. Mereo entered an option and license agreement with Sentynl Therapeutics for alvelestat, with eligibility for $40 million in upfront and R&D payments on option exercise, up to $435 million in milestones, and double-digit tiered U.S. royalties. For setrusumab, two Phase 3 studies in osteogenesis imperfecta did not meet primary fracture endpoints but showed statistically significant gains in bone mineral density and other measures, and Mereo and Ultragenyx are in regulatory discussions on a potential path forward.
Mereo BioPharma Group plc entered into an Option and License Agreement with Sentynl Therapeutics for the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The agreement grants Sentynl an exclusive option to license U.S. commercialization rights while Mereo retains commercial rights for the rest of the world.
Under the terms, Mereo will receive a non-refundable option fee and, upon option exercise, would be eligible for $40 million in upfront and R&D payments, up to $435 million in potential regulatory and commercial milestones, and double-digit tiered royalties on U.S. net sales. Sentynl would also fund the alvelestat Phase 3 development program on option exercise. Mereo will lead the global Phase 3 study and regulatory interactions until completion, while the companies collaborate during a short option period to refine the Phase 3 design and advance manufacturing.
Mereo BioPharma Group plc reported the results of its 2026 Annual General Meeting, where all resolutions passed. Shareholder turnout was high, with 436,766,255 ordinary shares represented in person or by proxy.
Shareholders adopted the annual report and accounts for the year ended December 31, 2025, with 98.29% of votes cast in favor, and re-appointed PricewaterhouseCoopers LLP as auditors with 98.59% support. The Audit and Risk Committee was authorized to determine PwC’s remuneration.
Investors approved the directors’ remuneration report with 93.35% support and the directors’ remuneration policy, effective after the AGM, with 91.74% support. The compensation of named executive officers received 91.71% advisory approval. Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz were each re-elected as directors, receiving around 94% of votes cast.
Shareholders also authorized the directors to allot shares and grant rights to subscribe or convert up to a maximum nominal amount of £3,591,354.73, and to do so on a non-pre-emptive basis, both authorities running until June 30, 2029. These replace earlier share issuance authorities to the extent not already used.
Mereo BioPharma Group plc filed an amended report to correct a technical item tag and reiterated its first quarter 2026 results and clinical updates. The company reported a net loss of $6.7 million for the quarter, improving from $12.9 million a year earlier, as operating loss narrowed and foreign currency gains increased.
Research and development expenses rose to $4.7 million, mainly from higher setrusumab costs, while general and administrative expenses fell to $4.0 million driven by ADR reimbursement and lower pre-commercial spending. Cash and cash equivalents were $36.2 million as of March 31, 2026, which the company expects to fund operations into mid-2027.
Clinically, neither of the two global Phase 3 studies of setrusumab in osteogenesis imperfecta met their primary fracture-rate endpoints, though both achieved strong results on key secondary measures such as bone mineral density and vertebral fractures. Mereo and partner Ultragenyx have started discussions with regulators on a potential pediatric path. Mereo is also preparing alvelestat for a single Phase 3 trial in AATD lung disease and expects its partner āshibio to start a Phase 2 vantictumab trial in ADO2 in the second half of 2026.
Mereo BioPharma Group plc reported first quarter 2026 results and updates on its rare disease pipeline. For the quarter ended March 31, 2026, net loss narrowed to $6.7 million from $12.9 million a year earlier, helped by lower general and administrative expenses of $4.0 million versus $7.3 million. Research and development spending rose to $4.7 million from $3.9 million, mainly from higher setrusumab costs.
Cash and cash equivalents were $36.2 million as of March 31, 2026, compared with $41.0 million at December 31, 2025, and the company reiterates that this is expected to fund operations into mid-2027. Setrusumab’s two Phase 3 studies in osteogenesis imperfecta did not reach their primary fracture endpoints but showed strong improvements in bone mineral density, vertebral fractures and patient-reported outcomes, with a safety profile consistent with prior studies. Mereo and partner Ultragenyx have begun discussions with regulators on a potential pediatric path.
Mereo is seeking a partner to run a single Phase 3 alvelestat trial in approximately 220 AATD-LD patients over 18 months and expects vantictumab partner āshibio to start a Phase 2 trial in ADO2 in the second half of 2026.
Mereo BioPharma Group plc reported that Dr. Annalisa Jenkins has informed the company she will not stand for re-election to its Board of Directors at the 2026 annual general meeting of shareholders scheduled for May 14, 2026.
She will continue to serve as a director until her current term expires immediately prior to that meeting. The company stated that Dr. Jenkins’ decision is not due to any disagreement with the company or the board regarding operations, policies, or practices, indicating a planned transition rather than a dispute-driven departure.
Mereo BioPharma reported a 2025 net loss of $41.9M, slightly improved from $43.3M in 2024, on $0.5M of revenue. Research and development expenses fell to $17.8M and general and administrative costs to $23.0M, reflecting lower spending on alvelestat, etigilimab and corporate functions.
Cash and cash equivalents were $41.0M as of December 31, 2025, down from $69.8M a year earlier, which the company expects to fund operations into mid‑2027. Shareholders’ equity stood at $40.9M.
In its pipeline, the Phase 3 Orbit and Cosmic studies of osteoporosis drug setrusumab in osteogenesis imperfecta did not meet primary fracture endpoints but showed strong bone mineral density gains, vertebral fracture reductions and positive patient‑reported outcomes, with further analyses ongoing. For alvelestat, Mereo has aligned with regulators on a single ~220‑patient Phase 3 trial in AATD‑lung disease and designed a potential Phase 2b bronchiectasis study to support partnering. The company also outlicensed vantictumab for osteopetrosis to āshibio, which plans a Phase 2 study in the second half of 2026.
Mereo BioPharma Group plc has received a Nasdaq notice that its American Depositary Shares have not met the required minimum bid price of $1.00 for 30 consecutive business days, putting its Nasdaq Capital Market listing at risk.
The company has 180 calendar days, until August 17, 2026, to regain compliance by having a closing bid price of at least $1.00 for 10 consecutive business days, a period Nasdaq staff may extend at its discretion. If compliance is not restored by then, Mereo could receive a further 180-day grace period if it meets other Nasdaq initial listing standards and commits to curing the deficiency. Failing that, the ADSs may be delisted, though the company could appeal. The ADSs continue to trade under “MREO,” and management states business operations are not currently affected, while acknowledging there is no assurance it will regain or maintain Nasdaq listing compliance.
Mereo BioPharma Group plc updated its liquidity outlook and provided new investor materials. The company reported cash and cash equivalents of $41 million as of December 31, 2025, which it now expects will fund operations to mid-2027, extending its projected cash runway. Mereo also issued a corporate update press release and posted an investor presentation for use at the J.P. Morgan Healthcare Conference and other meetings, which are furnished as exhibits and not deemed filed under U.S. securities laws.
Mereo BioPharma Group plc (MREO) furnished an update under Item 2.02, announcing financial results for the third quarter ended September 30, 2025, and recent corporate highlights. The full details are contained in a press release dated November 10, 2025, furnished as Exhibit 99.1.
The company noted that the information in Item 2.02 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act. MREO’s American Depositary Shares, each representing five ordinary shares, trade on The Nasdaq Stock Market LLC under the symbol MREO.
Mereo BioPharma Group plc furnished an update on its latest performance by announcing financial results for the second quarter ended June 30, 2025 and sharing recent corporate highlights. These details are provided in a press release dated August 12, 2025 that is attached as Exhibit 99.1.
The company is using this current report to make the press release available to investors, while specifying that the information is being furnished rather than filed for U.S. securities law purposes.